WILLOW BIOSCIENCES INC. ANNOUNCES COMPLETION OF SALE OF OPERATING SUBSIDIARY AND MANAGEMENT CHANGES

Rhea-AI Summary

Willow Biosciences has completed the sale of its operating subsidiary, Epimeron USA, to Mycofeast's U.S. subsidiary for US$2.76 million in cash. The transaction includes an escrow amount of US$275,975 held until September 17, 2025, subject to potential adjustments and indemnity claims.

Following the sale, significant management changes have occurred: CEO Dr. Chris Savile and SVP of Research and Development Dr. Trish Choudhary have resigned to join the purchaser. CFO Travis Doupe has been appointed as Interim CEO.

The company plans to use part of the proceeds for debt reduction while retaining the remainder pending a review of future cash requirements and potential opportunities. The transaction was executed through a share purchase agreement dated March 14, 2025, with detailed information available in the company's management information circular on SEDAR+.

Positive

• Sale of operating subsidiary Epimeron USA for US$2.76 million in cash
• Company plans to use proceeds for debt reduction

Negative

• Loss of key executives - CEO and SVP of R&D resigned to join buyer
• US$275,975 of sale price held in escrow until September 2025 with no guarantee of full payment
• Sale of operating subsidiary suggests significant restructuring/downsizing
• Interim CEO appointed, indicating leadership uncertainty

CALGARY, AB, April 30, 2025 /PRNewswire/ - Willow Biosciences Inc. (the "Company") (TSX: WLLW) (OTCQB: CANSF) announces the completion today of the sale (the "Transaction") of its wholly-owned operating subsidiary, Epimeron USA, Inc., to the U.S. subsidiary of Mycofeast Ltd., a privately-held, arms-length entity based in the United Kingdom (the "Purchaser"), pursuant to the terms of a share purchase agreement dated March 14, 2025 (the "Share Purchase Agreement"), between the Company and the Purchaser.

The Transaction was completed for aggregate consideration equal to US$2.76 million in cash following closing adjustments (the "Purchase Price"), of which US$275,975 (the "Escrow Amount") is subject in escrow until September 17, 2025, at which point the Company and the Purchaser will jointly instruct the escrow agent to pay the Company the balance of the Escrow Amount in excess of any amounts subject to indemnity claims and certain post-closing price adjustments. There is no guarantee that all or any portion of the Escrow Amount will be payable to the Company.

The Company intends to apply a portion of the Purchase Price to debt reduction, and will retain the remainder pending a review of its futures cash requirements and potential opportunities, with a view to maximizing shareholder value. Additional information concerning the Transaction is disclosed in the Company's management information circular dated March 26, 2025 (the "Information Circular"). Copies of the Share Purchase Agreement and the Information Circular are available on the Company's SEDAR+ profile at www.sedarplus.ca.  

As a condition to the completion of the Transaction, Dr. Chris Savile, President and Chief Executive Officer of the Company, and Dr. Trish Choudhary, Senior Vice President, Research and Development, resigned from their roles with the Company to join the Purchaser. Travis Doupe, Chief Financial Officer of the Company, has been appointed to the role of Interim Chief Executive Officer effective today. The Company's board of directors wishes to thank Dr. Savile and Dr. Choudhary for their service and wishes them both all the best in their future endeavours. 

Forward-Looking Statements. This news release may include forward-looking statements including opinions, assumptions, estimates and the Company's assessment of future plans and operations, and, more particularly, without limitation, statements concerning: anticipated use of proceeds from the Transaction; receipt of the Escrow Amount by the Company; and potential future opportunities. When used in this news release, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by the Company. Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

View original content to download multimedia:https://www.prnewswire.com/news-releases/willow-biosciences-inc-announces-completion-of-sale-of-operating-subsidiary-and-management-changes-302443366.html

SOURCE Willow Biosciences Inc.

FAQ

How much did Willow Biosciences (CANSF) sell Epimeron USA for in April 2025?

Willow Biosciences sold Epimeron USA for US$2.76 million in cash, with US$275,975 held in escrow until September 17, 2025.

What will Willow Biosciences do with the proceeds from the Epimeron USA sale?

Willow Biosciences plans to use part of the US$2.76 million proceeds for debt reduction and will retain the remainder while reviewing future cash requirements and potential opportunities to maximize shareholder value.

What management changes occurred at Willow Biosciences (CANSF) after the Epimeron sale?

CEO Dr. Chris Savile and SVP of R&D Dr. Trish Choudhary resigned to join the purchaser, while CFO Travis Doupe was appointed as Interim Chief Executive Officer.

When will Willow Biosciences receive the escrowed funds from the Epimeron sale?

The escrowed amount of US$275,975 is scheduled to be released on September 17, 2025, subject to any indemnity claims and post-closing price adjustments.

Who bought Epimeron USA from Willow Biosciences in 2025?

Epimeron USA was purchased by the U.S. subsidiary of Mycofeast, a privately-held company based in the United Kingdom.